202 related articles for article (PubMed ID: 37995640)
1. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
3. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
4. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
[TBL] [Abstract][Full Text] [Related]
5. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
Thakur G; Kumar V; Lee KW; Won C
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011337
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
Galatsis P
Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
[TBL] [Abstract][Full Text] [Related]
9. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
10. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.
Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H
J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171
[TBL] [Abstract][Full Text] [Related]
11. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y; Dzamko N
Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
13. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
14. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Taymans JM
Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782
[TBL] [Abstract][Full Text] [Related]
15. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
17. Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.
Tan S; Gong X; Liu H; Yao X
ACS Chem Neurosci; 2021 Sep; 12(17):3214-3224. PubMed ID: 34387082
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
Yao XY; Guan LN; Chen Q; Ren C
Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
Wojewska DN; Kortholt A
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]